Aspire Biopharma
ASBP
14 hedge funds and large institutions have $545K invested in Aspire Biopharma in 2025 Q2 according to their latest regulatory filings, with 8 funds opening new positions, 4 increasing their positions, 0 reducing their positions, and 7 closing their positions.
14% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 7
8% more funds holding
Funds holding: 13 → 14 (+1)
0% more ownership
Funds ownership: 0% → 0% (+0%)
38% less capital invested
Capital invested by funds: $876K → $545K (-$331K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PA
Procyon Advisors
Shelton,
Connecticut
|
+$217K |
| 2 |
CA
Crewe Advisors
Salt Lake City,
Utah
|
+$124K |
| 3 |
Jane Street
New York
|
+$51.7K |
| 4 |
OAS
Optivise Advisory Services
Franklin,
Tennessee
|
+$50.8K |
| 5 |
VAS
VR Advisory Services
Camana Bay, Grand Cayman,
Cayman Islands
|
+$38.4K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Toronto Dominion Bank
Toronto, Ontario,
Ontario, Canada
|
-$350K |
| 2 |
HCI
Harraden Circle Investments
New York
|
-$87.4K |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$17.5K |
| 4 |
TSS
Two Sigma Securities
New York
|
-$16K |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$15.7K |
ASBP Hedge Fund Activity: Q2 2025 in Review
14 of the 7,596 institutional investors tracked by Wall St. Rank reported a position in Aspire Biopharma (ASBP) for Q2 2025, worth a combined $545K — down 38% from $876K a quarter earlier.
Buyers outnumbered sellers: 8 funds opened new ASBP positions and 7 closed out — a net gain of 1 holder — while 4 added to existing stakes and 0 trimmed.
The largest buyer was Procyon Advisors, adding an estimated $217K. The largest seller was Toronto Dominion Bank, exiting entirely with an estimated $350K sold.
- 14 institutional investors held Aspire Biopharma (ASBP) as of Q2 2025, up from 13 in Q1 2025.
- Funds reported $545K of Aspire Biopharma stock for Q2 2025, down 38% quarter-over-quarter.
- 8 funds opened new Aspire Biopharma positions in Q2 2025 and 7 closed out, a net change of +1 holder.
- The largest Aspire Biopharma buyer in Q2 2025 was Procyon Advisors, an estimated $217K added.
- The largest Aspire Biopharma seller in Q2 2025 was Toronto Dominion Bank, an estimated $350K sold.
Based on aggregated 13F filings for Q2 2025.